Hill Dickinson advises Portage Pharmaceuticals on joint venture collaboration with University of Glasgow
Consultant, Michael Corcoran, from Hill Dickinson’s London corporate team has recently advised long-standing Canadian Securities Exchange listed client, Portage Biotech Inc. (OTCQB: PTGEF, Canadian Stock Exchange: PBT.U) (Portage) on its participation in a new joint venture project with the University of Glasgow to develop more effectively targeted drugs to treat chronic conditions including cancer.